PACIRA BIOSCIENCES, INC. Investing Cash Flow
PACIRA BIOSCIENCES, INC. (PCRX) reported Investing Cash Flow of $31.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $11.76M, a 81.08% decline year-over-year.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $19.44M.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $19.33M.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $43.61M.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2025 was $99.48M.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$83.28M, a 207.40% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2023 was $77.54M.
- PACIRA BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$225.19M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $31.20M 10-Q · filed 2026-08-04 | $50.53M derived: sum of 3 quarters · filed 2026-08-04 | $94.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $19.44M 10-Q · filed 2026-04-30 | $38.77M derived: sum of 2 quarters · filed 2026-04-30 | $82.39M derived: sum of 3 quarters · filed 2026-04-30 | $144.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $19.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $62.95M derived: sum of 2 quarters · filed 2026-02-26 | $125.11M derived: sum of 3 quarters · filed 2026-08-04 | $99.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | $43.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $105.78M derived: sum of 2 quarters · filed 2026-08-04 | $80.15M 10-Q · filed 2025-11-06 | $79.78M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $62.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $36.53M 10-Q · filed 2026-08-04 | $36.17M derived: sum of 3 quarters · filed 2026-08-04 | -$16.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$25.63M 10-Q · filed 2026-04-30 | -$26.00M derived: sum of 2 quarters · filed 2026-04-30 | -$78.16M derived: sum of 3 quarters · filed 2026-04-30 | -$93.38M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$368.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$52.53M derived: sum of 2 quarters · filed 2026-02-26 | -$67.75M derived: sum of 3 quarters · filed 2026-02-26 | -$83.28M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$52.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$67.38M derived: sum of 2 quarters · filed 2025-11-06 | -$82.91M 10-Q · filed 2025-11-06 | -$74.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$15.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$30.75M 10-Q · filed 2025-08-05 | -$22.37M derived: sum of 3 quarters · filed 2026-02-26 | -$26.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$15.53M 10-Q · filed 2025-05-08 | -$7.16M derived: sum of 2 quarters · filed 2026-02-26 | -$11.50M derived: sum of 3 quarters · filed 2026-02-26 | -$4.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $8.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.03M derived: sum of 2 quarters · filed 2026-02-26 | $11.36M derived: sum of 3 quarters · filed 2026-02-26 | $77.54M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$4.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.98M derived: sum of 2 quarters · filed 2024-11-06 | $69.17M 10-Q · filed 2024-11-06 | $80.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $7.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $73.51M 10-Q · filed 2024-07-30 | $84.70M derived: sum of 3 quarters · filed 2025-02-27 | $37.18M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $66.18M 10-Q · filed 2024-05-07 | $77.37M derived: sum of 2 quarters · filed 2025-02-27 | $29.86M derived: sum of 3 quarters · filed 2025-02-27 | $49.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$36.33M derived: sum of 2 quarters · filed 2025-02-27 | -$17.17M derived: sum of 3 quarters · filed 2025-02-27 | -$225.19M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$47.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$28.36M derived: sum of 2 quarters · filed 2023-11-02 | -$236.37M 10-Q · filed 2023-11-02 | -$169.46M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $19.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$188.86M 10-Q · filed 2023-08-02 | -$121.94M derived: sum of 3 quarters · filed 2024-02-29 | -$157.02M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$208.02M 10-Q · filed 2023-05-03 | -$141.10M derived: sum of 2 quarters · filed 2024-02-29 | -$176.18M derived: sum of 3 quarters · filed 2024-02-29 | -$173.15M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $66.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $31.84M derived: sum of 2 quarters · filed 2024-02-29 | $34.87M derived: sum of 3 quarters · filed 2024-02-29 | -$20.79M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$35.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$32.04M derived: sum of 2 quarters · filed 2022-11-03 | -$87.71M 10-Q · filed 2022-11-03 | -$170.03M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$52.63M 10-Q · filed 2022-08-03 | -$134.95M derived: sum of 3 quarters · filed 2023-02-28 | -$337.80M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$55.66M 10-Q · filed 2022-05-04 | -$137.98M derived: sum of 2 quarters · filed 2023-02-28 | -$340.83M derived: sum of 3 quarters · filed 2023-02-28 | -$304.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$82.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$285.16M derived: sum of 2 quarters · filed 2023-02-28 | -$249.04M derived: sum of 3 quarters · filed 2023-02-28 | -$277.61M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$202.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$166.72M derived: sum of 2 quarters · filed 2021-11-03 | -$195.29M 10-Q · filed 2021-11-03 | -$226.09M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $36.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $7.56M 10-Q · filed 2021-08-03 | -$23.24M derived: sum of 3 quarters · filed 2022-02-28 | -$17.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$28.57M 10-Q · filed 2021-05-04 | -$59.36M derived: sum of 2 quarters · filed 2022-02-28 | -$53.74M derived: sum of 3 quarters · filed 2022-02-28 | -$235.53M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$30.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$25.17M derived: sum of 2 quarters · filed 2022-02-28 | -$206.97M derived: sum of 3 quarters · filed 2022-02-28 | -$128.49M 10-K · filed 2022-02-28 |
| 2019-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$176.17M derived: sum of 2 quarters · filed 2020-10-30 | -$97.69M 10-Q · filed 2020-10-30 | -$220.86M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$181.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$103.32M 10-Q · filed 2020-08-06 | -$226.48M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2019-03-31 | $78.48M 10-Q · filed 2020-05-07 | -$44.68M derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2018-12-31 | -$123.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $20.58M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $143.74M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | -$223.76M 10-K · filed 2020-02-21 | |||
| 2011-06-30 | -$21.79M 10-Q · filed 2011-08-11 | |||
| 2010-06-30 | -$1.92M 10-Q · filed 2011-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |